Combination of Cystatins 9 and C Modulates Serum Biomarkers Associated with Inflammation and Provides Prophylactic as Well as Long-Term Protection against Multidrug-Resistant Klebsiella pneumoniae

We have identified recombinant human cystatins 9 (rCST9) and C (rCSTC) as a combination immunotherapeutic treatment against multidrug-resistant (MDR) New Delhi metallo-β-lactamase-1 (NDM-1)-producing We evaluated the lasting protection of rCST9/rCSTC treatment against MDR NDM-1 pneumonia. Results sh...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2019-05, Vol.63 (5)
Main Authors: Holloway, Alex J, Yu, JiehJuen, Arulanandam, Bernard P, Milligan, Gregg N, Eaves-Pyles, Tonyia D
Format: Article
Language:English
Subjects:
Animals
Cystatin C - metabolism
Cystatins
Cystatins - blood
Experimental Therapeutics
Immunomodulation - drug effects
Immunotherapy
Inflammation
Inflammation - blood
Klebsiella pneumoniae - drug effects
Mice
Mice, Inbred BALB C
Microbial Sensitivity Tests
Serum Amyloid A Protein - metabolism
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have identified recombinant human cystatins 9 (rCST9) and C (rCSTC) as a combination immunotherapeutic treatment against multidrug-resistant (MDR) New Delhi metallo-β-lactamase-1 (NDM-1)-producing We evaluated the lasting protection of rCST9/rCSTC treatment against MDR NDM-1 pneumonia. Results showed that rCST9/rCSTC treatment modulated endogenous serum biomarkers, cystatins 9 and C and amyloid A, associated with poor patient outcomes and provided prophylactic and long-term protection in a murine model of pneumonia.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.02519-18